Ardelyx, Inc. ARDX R2K
Healthcare · Biotechnology · United States
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
READ MORE ›$6.04
+64.58% 1Y
Market & Price
Market Cap
$1.49B
Current Price
$6.04
High / Low (52W)
$7.99 / $3.55
Beta
0.61
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
11.73
PEG Ratio
-
Book Value
$0.60
Price to Book
10.03
P/S
3.49
EV/EBITDA
-43.70
Dividend Yield
-
Profitability & Returns
ROCE
-7.80%
ROE
-39.46%
ROA
-5.11%
Profit Margin
-13.58%
Op Margin
-34.71%
EPS (Latest Qtr)
$-0.15
EPS (TTM)
$-0.24
Balance Sheet & Liquidity
Debt/Equity
1.58
Quick Ratio
2.93
Current Ratio
3.48
Debt
$234.13M
Total Assets
$501.60M
Current Assets
$382.32M
Working Capital
$293.71M
Ownership
Promoter Holding
3.19%
Chg in Prom Hold
-0.03%
FII / Inst Holding
70.64%
Chg in FII Hold
0.04%
Financial Snapshot
Enterprise Value
$1.49B
Total Revenue (TTM)
$427.68M
EBITDA
$-34.05M
Free Cash Flow
$86.38K
Operating Cash Flow
$-36.26M
Shares Outstanding
247.03M
Gross Margin
74.56%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
98.40%
Profit 5Y
2.78%
Revenue (YoY)
27.50%
Earnings (YoY)
-
PROS
- Compounding revenue at 98.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARDX Ardelyx, Inc. R2K | 6.04 | - | $1.49B | - | -7.80% | -39.46% | 98.40% | 2.78% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 2.32M | 30.00K | 172.00K | 85.00K | - | 18.00K | 3.01M | 2.25M | 1.21M | 1.84M | 2.71M | 1.81M | 6.58M | 1.31M | 1.17M | 468.00K | 2.53M | 4.99M | 11.37M | 22.33M | 56.39M | 46.02M | 73.22M | 98.24M | 74.11M | 97.66M | 110.33M | 125.22M | 94.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.30M | 12.40M | 3.98M | 10.85M | 4.81M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 33.60M | 1.86M | 30.00K | 170.00K | 85.00K | - | 18.00K | 2.41M | 2.25M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.81M | 85.26M | 106.35M | 114.37M | 89.66M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.16M | 99.65M | 101.68M | 109.27M | 122.45M |
| Operating Income | 9.06M | -18.08M | - | -23.53M | -28.69M | -29.20M | - | -28.43M | -26.42M | -21.23M | - | -17.68M | -22.15M | -23.73M | - | -25.50M | -24.83M | -22.09M | - | -21.77M | -24.21M | -17.16M | - | -32.01M | -44.83M | -42.24M | -27.81M | -26.21M | -21.88M | -26.06M | -16.62M | 7.40M | -24.68M | -13.63M | 2.23M | -36.35M | -14.39M | 4.67M | 5.10M | -32.79M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.42M | -11.87M | 8.02M | 8.10M | -29.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.26M | 6.58M | 7.98M | 7.58M | 6.92M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -40.28M | -19.08M | -867.00K | -400.00K | -37.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 859.00K | 1.00K | 102.00K | 7.00K | 8.00K |
| Net Income | 9.01M | -18.13M | -17.00M | -23.47M | -28.61M | -29.03M | -31.28M | -28.01M | -25.72M | -20.72M | 10.11M | -17.02M | -22.29M | -24.13M | -27.86M | -26.14M | -25.47M | -23.54M | -19.79M | -22.37M | -24.96M | -18.11M | -28.88M | -33.16M | -45.19M | -43.59M | -28.07M | -26.94M | -22.89M | -26.77M | -17.12M | 6.63M | -26.52M | -16.45M | -809.00K | -41.14M | -19.08M | -969.00K | -407.00K | -37.60M |
| Diluted EPS | 0.42 | -0.70 | -0.65 | - | -0.83 | - | - | -0.59 | -0.54 | -0.44 | 0.21 | - | - | - | - | - | - | - | - | -0.25 | -0.28 | -0.20 | - | -0.34 | -0.45 | -0.42 | -0.21 | -0.19 | -0.14 | -0.13 | -0.08 | 0.03 | -0.11 | -0.07 | 0.00 | -0.17 | -0.08 | 0.00 | 0.00 | -0.15 |
| R&D Expense | 6.20M | 14.71M | - | 19.25M | 23.84M | 24.86M | - | 22.39M | 20.57M | 15.37M | - | 13.35M | 16.05M | 17.94M | - | 20.38M | 19.48M | 17.58M | - | 15.84M | 18.86M | 12.24M | - | 20.46M | 26.02M | 23.70M | 8.85M | 9.74M | 7.47M | 9.09M | 8.28M | 8.64M | 10.58M | 12.76M | 15.31M | 14.94M | 15.67M | 18.07M | - | 20.19M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 42.00M | 2.61M | 5.28M | 7.57M | - | 52.16M | 124.46M | 333.62M | 407.32M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 4.12M | 17.80M | 50.56M | 39.54M |
| Gross Profit | - | - | - | 24.03M | - | 33.60M | 2.14M | 4.68M | - | - | 48.04M | 106.66M | 283.06M | 367.78M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 111.80M | 169.94M | 311.01M | 408.76M |
| Operating Income | -8.80M | -2.87M | -1.56M | -29.39M | -112.89M | -65.11M | -90.95M | -91.26M | -90.78M | - | -63.76M | -63.28M | -27.95M | -40.98M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -60.98M | -55.35M | -16.71M | -29.17M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 5.07M | 8.87M | 20.09M | 28.40M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -67.20M | -65.52M | -38.87M | -60.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 8.00K | 547.00K | 266.00K | 969.00K |
| Net Income | -9.79M | -6.56M | -3.21M | -29.62M | -112.39M | -64.34M | -91.30M | -94.94M | -94.31M | - | -67.21M | -66.07M | -39.14M | -61.60M |
| Diluted EPS | - | - | - | - | - | - | - | -1.47 | -1.05 | - | -0.42 | -0.30 | -0.17 | -0.26 |
| R&D Expense | 10.18M | 28.09M | 25.90M | 39.88M | 94.16M | 75.48M | 69.37M | 71.68M | 65.05M | 91.14M | 35.20M | 35.54M | 52.32M | 71.53M |
Compounded Sales Growth
| 5 Years: | 98.40% |
| 1 Year: | 27.50% |
Compounded Profit Growth
| 5 Years: | 2.78% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +64.58% |
| 6 Months: | +5.59% |
| 3 Months: | -7.79% |
| 1 Month: | +0.50% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 42.90M | 113.41M | 116.95M | 213.13M | 157.90M | - | 183.33M | 259.78M | 201.56M | - | 190.07M | 297.58M | 435.75M | 501.60M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 153.60M | 246.11M | 356.45M | 382.32M |
| Cash & Equivalents | 10.78M | 32.90M | 34.44M | 107.29M | 107.00M | 74.60M | 75.38M | - | 78.77M | 181.13M | 91.03M | - | 96.14M | 21.47M | 64.93M | 68.00M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 3.28M | 12.45M | 21.17M | 17.73M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 7.73M | 22.03M | 57.70M | 71.85M |
| Total Liabilities | - | - | 50.23M | 52.73M | 8.04M | 19.98M | 18.59M | - | 67.52M | 73.13M | 75.45M | - | 91.74M | 130.76M | 262.46M | 334.65M |
| Current Liabilities | - | - | 17.14M | 21.54M | 7.72M | 19.20M | 17.87M | 1.00M | 17.73M | 22.22M | 28.42M | - | 65.60M | 50.39M | 77.83M | 88.61M |
| Long Term Debt | - | - | - | - | - | - | - | - | 51.98M | 50.01M | 50.79M | - | - | 49.82M | 150.85M | 202.83M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 36.46M | 55.98M | 153.44M | 207.95M |
| Total Equity | -48.26M | -57.39M | -63.48M | 60.68M | 108.90M | 193.15M | 139.31M | - | 115.81M | 186.66M | 126.11M | - | 98.33M | 166.82M | 173.29M | 166.95M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 198.58M | 232.45M | 238.02M | 244.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -71.84M | -92.53M | -65.19M | -70.27M | -76.48M | -81.44M | - | -70.04M | -89.72M | -44.81M | -42.48M |
| Investing Cash Flow | - | - | - | -3.45M | -131.08M | 65.29M | -29.89M | 23.37M | -31.44M | - | 18.41M | -131.25M | -18.32M | -8.96M |
| Financing Cash Flow | - | - | - | 75.01M | 191.20M | 685.00K | 103.55M | 155.48M | 22.78M | - | 75.34M | 146.29M | 106.59M | 54.51M |
| Capital Expenditure | -128.00K | -278.00K | -1.86M | -3.45M | -4.87M | -2.35M | -311.00K | -325.00K | -324.00K | - | -55.00K | -344.00K | -1.01M | -1.49M |
| Free Cash Flow | - | - | - | -75.29M | -97.40M | -67.55M | -70.58M | -76.81M | -81.76M | - | -70.10M | -90.06M | -45.82M | -43.98M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 23.71M | -74.67M | 43.46M | 3.07M |
| Share Buybacks | 20.00K | 2.00K | 2.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 80.0% | 82.1% | 88.6% | - | - | 92.1% | 85.7% | 84.8% | 90.3% |
| Operating Margin % | - | - | - | - | - | -155.0% | -3,488.6% | -1,728.1% | -1,199.0% | - | -122.2% | -50.8% | -8.4% | -10.1% |
| Net Margin % | - | - | - | - | - | -153.2% | -3,502.0% | -1,797.8% | -1,245.7% | - | -128.9% | -53.1% | -11.7% | -15.1% |
| ROE % | 17.0% | 10.3% | -5.3% | -27.2% | -58.2% | -46.2% | -78.8% | -50.9% | -74.8% | - | -68.3% | -39.6% | -22.6% | -36.9% |
| ROCE % | - | -11.1% | -1.7% | -26.9% | -58.2% | -46.5% | -54.9% | -38.4% | -52.4% | - | -51.2% | -25.6% | -7.8% | -9.9% |
Shareholding Pattern
Insiders
3.19%
Institutions
70.64%
Public Float
72.97%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.57% | 21.16M | $127.83M |
| 2 | Millennium Management Llc | 7.22% | 17.84M | $107.77M |
| 3 | State Street Corporation | 5.51% | 13.60M | $82.17M |
| 4 | Vanguard Capital Management LLC | 4.20% | 10.37M | $62.61M |
| 5 | Janus Henderson Group PLC | 3.39% | 8.37M | $50.56M |
| 6 | Nomura Asset Management International Inc | 3.31% | 8.17M | $49.34M |
| 7 | Vanguard Portfolio Management LLC | 2.70% | 6.66M | $40.24M |
| 8 | Geode Capital Management, LLC | 2.43% | 6.01M | $36.29M |
| 9 | Nuveen, LLC | 2.12% | 5.23M | $31.62M |
| 10 | Two Sigma Investments, LP | 1.73% | 4.27M | $25.82M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARDX
No recent headlines available.